Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Price:
50.92
USD
0.91%
Market Cap:
$2.9B
Relative Value
The Relative Value of one
SUPN
stock under the Base Case scenario is
33.68
USD.
Compared to the current market price of 50.92 USD,
Supernus Pharmaceuticals Inc
is
Overvalued by 34%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
SUPN
Relative Value
Base Case
33.68
USD
Overvaluation 34%
Multiples Across Competitors
SUPN Competitors Multiples
Supernus Pharmaceuticals Inc Competitors
Supernus Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
|
2.9B USD | 4.1 | -75.9 | 113.2 | -42 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
935.4B USD | 14.3 | 45.1 | 30.4 | 32.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.9B USD | 6.2 | 21.7 | 15.1 | 18.5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
256.9B CHF | 4.2 | 19.8 | 11.7 | 13.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
233.7B CHF | 5.3 | 21.5 | 13.3 | 17.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
222.2B GBP | 5.1 | 29.1 | 16.1 | 22.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
288.9B USD | 4.4 | 15.7 | 9.8 | 11.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.8 | 8 | 9.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.2B USD | 2.4 | 19.5 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.9B USD | 2.5 | 16.8 | 7.1 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
